Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Docetaxel (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 26 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Jun 2017 Biomarkers information updated
- 10 Oct 2016 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.